AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

Eloralintide research guide

Amylin peptide analogue with a selective receptor profile in experimental assays

Eloralintide / LY3841136 evidence from receptor experiments and human trials, including the limits of comparing it with other amylin analogues.

AUS Peptide Supply editorial team
LY3841136

01 · Identity

What the name identifies

Eloralintide is the amylin peptide analogue identified by the research code LY3841136. Its discovery work examined human and rat amylin receptor systems and the calcitonin receptor. It is a separate molecule from cagrilintide, not a different vial size or synonym for that compound. Findings about combinations with other agents must retain the identities of every component.

02 · Evidence position

What the literature can support

The selected primary evidence spans receptor assays, animal work and randomised human studies of clinical formulations. The 2025 discovery paper measured a receptor preference in particular assay systems; it does not establish uniform selectivity in every tissue or species. Human study results describe the investigated formulation and participants, not the properties of a separately supplied powder.

03 · Study-level map

Evidence and its limits

Preclinical

What did the receptor experiments distinguish?

The 2025 discovery paper found preferential activation of human AMY1 receptors relative to the human AMY3 and calcitonin receptors tested. The rat receptor pattern differed, illustrating why species and receptor construct matter.

Limit: Receptor preference is an assay finding. It does not by itself predict clinical superiority or establish the activity of a catalogue sample.

Human early-phase

What did the 12-week proof-of-concept study assess?

A phase 1 randomised study reported in 2026 enrolled 100 participants with overweight or obesity and assessed pharmacokinetics, tolerability and pharmacodynamic outcomes over 12 weeks. Adverse events and body-weight changes were reported.

Limit: A limited-duration early study cannot settle long-term outcomes, rare events or equivalence of a different formulation.

Human randomised

What does the 48-week trial add?

The 2025 placebo-controlled trial enrolled 263 adults with overweight or obesity without type 2 diabetes. It reported greater mean body-weight reductions in the eloralintide groups than placebo over 48 weeks; nausea and fatigue were common adverse events.

Limit: The selected population, trial preparation, treatment groups and efficacy analysis define the result. It is not a performance promise for research material.

04 · Analytical context

Questions a batch record should answer

  1. 01Does the identity specification explicitly match eloralintide / LY3841136, including relevant structural modifications?
  2. 02Are measured content, chromatographic purity and any functional receptor assay reported as separate properties?
  3. 03Do sample identifiers, analysis dates and lot records support a connection between any report and the material offered?

05 · Boundary conditions

What this record does not establish

  • Cagrilintide and eloralintide have separate identities and source records; a shared amylin label does not make them interchangeable.
  • No matching APS analytical report for Eloralintide 10mg was verified for this guide.
  • The cited trials do not validate the purity, stability or receptor activity of an independent catalogue vial.

Sources checked

  1. 1.
    Eloralintide discovery, receptor characterisation and initial clinical study

    Briere et al. — Molecular Metabolism · 2025 · Primary study

  2. 2.
    Eloralintide: 12-week phase 1 proof of concept

    Bhattachar et al. — Diabetes, Obesity and Metabolism · 2026 · Primary study

  3. 3.
    Eloralintide in a 48-week randomised placebo-controlled trial

    Billings et al. — The Lancet · 2025 · Primary study

Continue through the topic